TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* hypertension~* angina pectoris CCS class II-IV~* objective signs of ischemia on exercise-ECG or myocardial SPECT~* no significant stenosis on angiography (minimal lumen diameter \>50% of relevant reference segment)~Exclusion Criteria:~* known allergy to any study medication~* abnormal lab tests of clinical significance~* valvular disease of haemodynamic significance~* known secondary hypertension~* atrial fibrillation or other significant arrythmias~* myocardial infarction \< 30 days before inclusion~* resting angina \< one week before inclusion~* known endocrine disease, nephropathy or hepatic disease~* present malignant disease~* pregnancy~* fertile women not using safe contraceptives \> 6 months before inclusion. Use of contraceptives must continue 1 month after completion or retraction from the study~* body mass index \> 30~* significant chronic obstructive lung disease (FEV1 \< 1.5 l)~* participant in another study including test medicine~* present treatment with dipyridamole~* present treatment with phosphodiesterase-5-inhibitors that the patient does not want to discontinue during the study period~* heart transplanted patients~* patients with magnetizable metallic implants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Vasodilatory (Type: EXPERIMENTAL): Patients in this arm will receive intensive vasodilatory treatment to lower blood pressure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Investigate the Activity of Endotoxin in Severe Sepsis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* ICU patients with new onset of severe sepsis and septic shock~* Presence of at least 2 of the following conditions (These criteria should have occurred between 12 hours before or 6 hours after the onset of the qualifying first organ dysfunction)~* Fever or hypothermia (body temperature over 38 ℃ or under 36 ℃~* Tachycardia (heart rate \> 90 bpm)~* Tachypnea (respiratory rate over 20 breaths/min or under mechanical ventilation)~* Leukocyte count more than 12,000 cells/mm3, less than 4,000 cells/mm3, or more than 10 % of immature form (band)~Exclusion Criteria:~Patient will be excluded if they~* are under 20 years old or older than 99 years old~* have suffered from severe sepsis or septic shock more than 24 hours~* are pregnant~* were treated with another medicine or device in the trial less than 30 days prior to the admission to this trial~* have received organ transplantation less than 1 years prior to this trial~* are terminally ill, for examples with metastasis, with a life expectancy of less than 30 days (certified by the attending physician)~* have already received other blood cleaning treatments, such as CVVH, HD, HF, and PE upon entry into the trial~* have chosen palliative care and signed Do Not Resuscitate sheet~* non-native speaker

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Severe Sepsis (Type: None): Patient with severe sepsis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Novel Formulation of Pasteurized Maple Cough Syrup Compared With Placebo on Nocturnal Cough and Sleep Quality in Infants With Upper Respiratory Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Otherwise healthy male or female infant who is between 0 and 12 months of age.~2. Presents to clinic with a URI characterized by the presence of rhinorrhea and cough for 7 or fewer days' duration.~3. Patient is an appropriate candidate, in the judgment of the investigator, to participate in the study.~4. Parents/caregivers provide an answer of at least somewhat (3 points on a 7-point Likert scale) for a minimum of 2 of the 3 questions related to nocturnal cough frequency, effect on child's sleep, and effect on parental/caregiver sleep based on the previous night's symptoms (see Section 11.0).~5. Parent/legal authorized representative provides written informed consent for child to participate in study.~6. Parent/caregiver who is willing and able to comply with study requirements.~Exclusion Criteria~1. Signs or symptoms of a more treatable disease (eg, asthma, pneumonia, laryngotrachebronchitis, sinusitis, allergic rhinitis).~2. Diagnosis of influenza, bronchiolitis or respiratory syncytial virus (RSV).~3. History of reactive airways disease, asthma, or chronic lung disease.~4. Use of any medication to treat cough within 6 hours of bedtime on the evening prior to or on the day of enrollment. (Use of analgesic medications such as acetaminophen or ibuprofen is not exclusionary.)~5. Presence of any significant disease including immunodeficiency, hepatic, renal, cardiovascular, or hematologic disease or any other health condition that, in the opinion of the investigator, would preclude participation in the study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Months
- Healthy Volunteers: f

Study Arms:
- Novel formulation of pasteurized maple cough syrup (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: PDS vs Polyamide for Midline Abdominal Closure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients above 12 years of age undergoing midline abdominal fascial closure using a continuous technique in the Department of Surgery, Christian Medical College and Hospital~Exclusion Criteria:~* All patients under 12 years of age~* Gynaecological operations~* Abdominal wall hernia repair

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Surgical Patient undergoing midline laparotomy closure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Novel Biomarkers for Invasive Aspergillosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 16y at start of study~* One of the following diagnoses:~* De novo, refractory or relapsed AML/MDS receiving intensive chemotherapy~* De novo, refractory or relapsed ALL/T-lymphoblastic lymphoma receiving intensive chemotherapy~* Aplastic anemia requiring ATG therapy~* Any patient admitted for either autologous or allogeneic hematopoietic stem cell transplantation~* Written informed consent obtained from the patient~Exclusion Criteria:~* AML or ALL beyond the specified inclusion criteria~* Directed treatment for possible, probable, or proven invasive aspergillosis, at moment of screening, or with end of treatment \< 6 weeks at screening, or no complete response according to EORTC/MSG criteria, or complete response achieved \< 6 weeks at time of screening.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Total cohort (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current or prior chronic Hepatitis C infection as documented by detectable HCV RNA in prior 5 years~* Child-Turcotte-Pugh stage A5-B8. Cirrhosis diagnosis may be based on either histological criteria (an previous liver biopsy showing F4/4 or F5-6/6 fibrosis) or clinical criteria (nodular liver on abdominal imaging, splenomegaly, thrombocytopenia, spider telangiectasias, palmar erythema, ascites, varices).~* Platelet count \< 175,000/ul~* Subject capable of giving informed consent~Exclusion Criteria:~* Active alcohol use \> 20g/d~* Current or planned (within following 6 months) antiviral therapy for hepatitis C~* HIV co-infection~* Diagnosis of overt hepatic encephalopathy~* Current lactulose use~* Exposure to rifaximin, rifampin or rifabutin within 12 months~* History of C. difficile colitis~* History of adverse drug reaction or sensitivity to rifaximin, rifampin or rifabutin or any inactive components of rifaximin~* Pregnancy~* Anemia with hemoglobin \< 10g/dl or hematocrit \< 30%~* Chronic kidney disease with creatinine \> 2.1mg/dl~* Total bilirubin \> 3.0g/dl~* Active non-hepatic medical conditions such as congestive heart failure, chronic lung disease requiring oxygen, coronary artery disease with unstable angina~* Requirement for chronic immunosuppressive therapy such as corticosteroids, cyclophosphamide, azathioprine, TNF-alpha antagonists~* Chronic autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis~* Post-liver transplantation status or anticipated liver transplantation within 6 months.~* Systemic antimicrobial exposure within 30 days of planned Visit 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Rifaximin/Placebo (Type: EXPERIMENTAL): Rifaximin 550mg po bid for 12 weeks followed by crossover to matched placebo po bid x 12 weeks
- Placebo/Rifaximin SSD (Type: EXPERIMENTAL): Matched placebo po bid for 12 weeks followed by crossover to Rifaximin 550mg po bid x 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MIdazolam Versus MOrphine in Acute Pulmonary Edema (MIMO Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with acute pulmonary edema with dyspnoea and anxiety~Exclusion Criteria:~* Patients with known severe liver disease.~* Patients with known severe renal disease.~* Patients with expectation of death from other illness during the course of the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- midazolam (Type: EXPERIMENTAL): The dose of midazolam intravenously will be of 1 mg which may be repeated until a total dose of 3 mg.
- morphine (Type: ACTIVE_COMPARATOR): The dose of morphine intravenously is of 2-4 mg which may be repeated until a total dose of 8 mg if the patient continue suffering from severe anxiety or distress caused by APE

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All neonates (0-29 days old) less than or equal to 33 post-menstrual age at time of PDA diagnosis requiring nasal CPAP or mechanical ventilation~* Echo confirmed PDA with a transductal diameter of 1.5 mm or greater and demonstrating a left-to-right shunt~* Signed informed consent~Exclusion Criteria:~* Presence of: ductal-dependent congenital heart disease, pulmonary hypertension,~* Active bleeding (including Grade 3 or 4 IVH)~* Platelet count \< 100,000~* Coagulopathy~* Suspected NEC~* Suspected perforation~* Creatinine \> 1.5~* Hyperbilirubinemia requiring exchange transfusion~* Hypotension requiring pressor support~* Life-threatening congenital malformation

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 29 Days
- Healthy Volunteers: f

Study Arms:
- Optimized Ibuprofen (Type: EXPERIMENTAL): None
- Standard Ibuprofen (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Results of Bile and Blood Culture in Patients With Acute Cholangitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with moderate or severe cholangitis which fullfilled the criteria by the Tokyo Guidelines (Tanaka A, Takada T, Kawarada Y, et al. Antimicrobial therapy for acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg 2007;14:59-67.)~* Patients who are successfully treated with endoscopic or radiologic biliary drainage~* Patients who undergo both blood and bile culture tests~Exclusion Criteria:~* Patients with other infections except cholangitis or cholecystitis~* Patients who received surgical biliary drainage treatment~* Patients who are treated with endoscopic or radiologic biliary drainage more than 24 hours after using initial antibiotics~* Patients who does not agree with informed consent or who are vulnerable subjects

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* First time appointment for a patient at designated optometry office for treatment of symptoms associated with Vertical Heterophoria~* Must have symptoms of dizziness or headache or both:~  * Dizziness defined as one or more of these: lightheadedness,dizziness, vertigo, feeling off-balance, lack of coordination / clumsy, unsteadiness while walking or drifting / veering to one side while walking, motion sickness~ * Headache defined as one or more of these: pain anywhere in the head,posterior neck / upper trapezius (upper back), face, and in and / or around the eyes~* Duration of symptoms greater than 4 months~* Evaluated for these symptoms previously by at least 1 other doctor (General Practice, Family Practice, Internal Medicine, Neurology, ENT, Emergency Medicine, Pediatrics, PM\&R, Ophthalmology).~* Age \>14~* The patient (or their representative) must be able and willing to fill out extra paperwork~* All Patients to be seen by same Optometrist for all visits~* Must be willing to wear glasses.~* The patient (or their representative) must be able to sign informed consent~* Must have a driver for Follow Up visits where Control and Treatment Glasses are dispensed, and when Washout period is initiated~* Must have a driver for Follow Up visits where Control and Treatment Glasses are dispensed, and when Washout period is initiated~* Must have previous negative Neuroimaging (HCT or MRI) that was ordered to assess for headache and / or dizziness~Exclusion Criteria:~* Previous diagnosis of strabismus, vertical heterotropia, CN 3, 4 or 6 palsy, lazy eye~* Previous eye injury or eye operation (including RK and Lasik)~* Diagnosis of glaucoma~* Diagnosis of cataracts~* Diagnosis of proptosis~* Previous C-spine surgery / fusion~* Previous Rx contains prismatic correction~* \>18 PD of exophoria~* \> 4 PD of vertical heterophoria on Initial Exam

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard (Treatment) (Type: ACTIVE_COMPARATOR): None
- Placebo (control) (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy of a Global Dental Health Promotion Program on Dental Hygiene in Patients With Schizophrenia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a confirmed diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM V)~* Managed at a specialized establishment~* Older than 18 years.~* who have provided written informed consent to take part in the study~Exclusion Criteria:~* Fully hospitalized patients~* Patients who are unstable from a psychiatric poit of view or who suffer from delirium.~* Subjects with less than one incisor, canine, premolar and molar on each hemi-arch~* Patients with a risk of infectious endocarditis or a major risk of superinfection~* Patients on long-term treatment with antibiotics (Impact of antibiotherapy on oral flora)~* Patients treated with chemotherapy~* Pregnant or breastfeeding women~* Patients without National Health Insurance cover.~* Poor written and/or oral comprehension of the French language

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): None
- Surveillance (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Reduction of Corticosteroid Use in Outpatient Treatment of Exacerbated COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent as documented by signature~* Age ≥40 years~* History of ≥10 pack-years of smoking (past or present smokers)~* Airway obstruction, defined as FEV1/FVC≤70%~* Current acute exacerbation of COPD by clinical criteria, defined by the presence of at least two of the following:~  * Change of baseline dyspnea~ * Change of cough~ * Change of sputum quantity or purulence~Exclusion Criteria:~* Diagnosis of asthma~* Initial necessity of hospitalization~* Women who are pregnant or breast feeding~* Premenopausal women with insufficient contraception and anamnestic risk for pregnancy~* Severe coexisting disease with life expectancy \<6 months~* Diagnosis of tuberculosis~* Known severe immunosuppression or immunosuppression after solid organ or stem cell transplantation~* Inability to follow study procedures, e.g. due to language problems, psychological disorders, dementia, etc. of the participant~* Participation in another study involving an investigational drug~* Previous enrolment into the current study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Investigational treatment (Type: EXPERIMENTAL): Patients included in the placebo group are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for three days followed by two days of placebo.
- Standard treatment (Type: ACTIVE_COMPARATOR): Patients included in the control group are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for five days as recommended in current guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Management of Drug Hypersensitivity in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participation will be proposed to any children (0 to 16 years) receiving one or several drug(s) and developing one of the following clinical manifestations: urticaria, maculopapular rash, bullous eruption, flush, anaphylaxis, serum sickness-like disease, SJS, TEN, DRESS or fever linked to drug intake.~Exclusion Criteria:~* Patients will be excluded if the symptoms occur more than 72 hours after any treatment was stopped or if the symptoms are clearly linked to another cause (measles, rubeola, roseola, varicella, fifth disease, Gianotti-Crosti syndrome, scarlet fever, Gibert's pityriasis or food allergy).

- Gender: ALL
- Minimum Age: None
- Maximum Age: 16 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues